Solid result. Revenue growth of almost 20%. Very much doubt there will be a selloff here. NPAT will increase by a larger portion in the coming years as the chip shortages subsides and the EBTIDA ratio is restoored to previous highs. We are probably looking at Revenue growth of mid to high teens and NPAT growth of high teens for a few years to come assisted by the Philips fiasco.
Ann: ResMed Announces Results for the First Quarter of FY2022, page-2
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$30.60 |
Change
-0.670(2.14%) |
Mkt cap ! $19.39B | |||
| Open | High | Low | Value | Volume |
| $30.37 | $30.64 | $30.12 | $86.17M | 2.818M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 327 | $30.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $30.63 | 57 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |